ORIC Oric Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1796280 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-15.2%
TTM EPS YoY15.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-41.8%
ROA-39.1%
ROIC (approx.)-40.8%
Asset turnover—
Leverage & solvency
Liabilities / assets7.5%
Debt / equity0.00x
Current ratio11.09x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $109.82M | $114.07M | $85.17M | $61.68M | $56.86M |
| SG&A expense | $33.19M | $28.82M | $25.61M | $25.09M | $22.01M |
| Operating income | -$143.00M | -$142.90M | -$110.78M | -$91.77M | -$78.87M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$129.47M | -$127.85M | -$100.70M | -$89.12M | -$78.72M |
| EBITDA | -$141.78M | -$141.79M | -$109.75M | -$90.80M | -$77.97M |
| EPS (basic) | -1.47 | -1.83 | -1.96 | -2.25 | -2.07 |
| EPS (diluted) | -1.47 | -1.83 | -1.96 | -2.25 | -2.07 |
| Weighted avg. shares (diluted) | 87.79M | 69.73M | 51.45M | 39.66M | 37.95M |
| Balance sheet | |||||
| Cash & equivalents | $45.67M | $59.90M | $23.88M | $67.31M | $226.47M |
| Short-term investments | $235.82M | $196.55M | $184.80M | $139.43M | $10.97M |
| Current assets | $288.47M | $262.25M | $212.60M | $210.46M | $240.52M |
| PP&E, net | $2.42M | $2.92M | $2.86M | $3.25M | $2.41M |
| Total assets | $408.89M | $274.14M | $252.01M | $247.18M | $298.64M |
| Current liabilities | $20.42M | $24.85M | $20.46M | $15.39M | $15.15M |
| Long-term debt | — | — | — | — | $10.50M |
| Total debt | — | — | — | — | $10.50M |
| Total liabilities | $24.53M | $31.02M | $27.92M | $24.83M | $25.67M |
| Shareholders' equity | $384.36M | $243.12M | $224.09M | $222.35M | $272.98M |
| Net debt | — | — | — | — | -$215.97M |
| Shares outstanding | 98.53M | 71.02M | 54.87M | 45.09M | 39.43M |
| Cash flow statement | |||||
| Operating cash flow | -$110.97M | -$112.66M | -$85.69M | -$75.14M | -$59.54M |
| Capital expenditure | $712,000 | $1.19M | $849,000 | $2.08M | $939,000 |
| Free cash flow | -$111.68M | -$113.85M | -$86.54M | -$77.22M | -$60.48M |
| Investing cash flow | -$148.03M | $22.14M | -$43.40M | -$109.25M | $158.44M |
| Financing cash flow | $245.26M | $126.55M | $85.66M | $25.23M | $49.13M |
| Depreciation & amortization | $1.22M | $1.11M | $1.03M | $966,000 | $897,000 |
| Stock-based compensation | $25.04M | $20.21M | $15.23M | $14.46M | $12.85M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.